17 assets in Oropharynx Squamous Cell Carcinoma

Therapeutic assets addressing Oropharynx Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
e7 tcr-t cells Oropharynx Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
Cabozantinib Oropharynx Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Oropharynx Squamous Cell Carcinoma	ImmunityBio, Inc.	P2	CCC (53)
had5-hpv vaccine Oropharynx Squamous Cell Carcinoma	ImmunityBio, Inc.	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Oropharynx Squamous Cell Carcinoma	Regeneron Pharmaceuticals	P2	CCC (53)
Nivolumab Oropharynx Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Docetaxel Oropharynx Squamous Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
SX682 Oropharynx Squamous Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Vidutolimod Oropharynx Squamous Cell Carcinoma	Regeneron Pharmaceuticals	P2	CC (45)
Nogapendekin Alfa Inbakicept Oropharynx Squamous Cell Carcinoma	ImmunityBio, Inc.	P2	CC (44)
Tsc-200-A0201 Oropharynx Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-201-B0702 Oropharynx Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-202-A0201 Oropharynx Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-203-A0201 Oropharynx Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0101 Oropharynx Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0201 Oropharynx Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-C0702 Oropharynx Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)